The Law Office of Robbins Umeda LLP Announces an Investigation of the Acquisition of Clarient, Inc. by GE Healthcare
22 Octubre 2010 - 2:39PM
Business Wire
Robbins Umeda LLP has commenced an investigation into possible
breaches of fiduciary duty and other violations of state law by
members of the Board of Directors ("Board") of Clarient, Inc.
("Clarient" or the "Company") (NASDAQ:CLRT) in connection with
their efforts to sell Clarient to GE Healthcare, a unit of General
Electric Company (NYSE: GE). If the transaction is completed,
Clarient shareholders will receive $5.00 in cash for each share of
Clarient common stock they hold and $20.00 in cash for each share
of Clarient preferred stock they hold. The transaction is expected
to close in late 2010 or early 2011.
Robbins Umeda LLP's investigation concerns whether Clarient's
Board undertook a fair process to obtain fair consideration for all
shareholders of Clarient. Specifically, our investigation concerns
whether the Company's Board breached their fiduciary duties to
Clarient shareholders by failing to adequately shop the Company
before entering into the transaction with GE Healthcare.
If you are a shareholder of Clarient, plan to continue to hold
your shares, and would like more information about your rights as a
shareholder, please contact attorney Gregory E. Del Gaizo at
800-350-6003 or by e-mail at info@robbinsumeda.com.
Robbins Umeda LLP is a securities litigation firm with
significant experience representing investors in merger-related
shareholder class actions, shareholder derivative actions, and
securities fraud class actions. For more information about the
firm, please go to http://www.robbinsumeda.com.
Advertisement
Clarient, Inc. (MM) (NASDAQ:CLRT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Clarient, Inc. (MM) (NASDAQ:CLRT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Clarient, Inc. (MM) (NASDAQ): 0 recent articles
Más de Robbins Umeda LLP Artículos de Noticias